CL2021002294A1 - Compuestos, composiciones y métodos para el tratamiento de enfermedad - Google Patents

Compuestos, composiciones y métodos para el tratamiento de enfermedad

Info

Publication number
CL2021002294A1
CL2021002294A1 CL2021002294A CL2021002294A CL2021002294A1 CL 2021002294 A1 CL2021002294 A1 CL 2021002294A1 CL 2021002294 A CL2021002294 A CL 2021002294A CL 2021002294 A CL2021002294 A CL 2021002294A CL 2021002294 A1 CL2021002294 A1 CL 2021002294A1
Authority
CL
Chile
Prior art keywords
compositions
compounds
methods
disease
treatment
Prior art date
Application number
CL2021002294A
Other languages
English (en)
Inventor
Radhakrishnan P Iyer
Seetharamaiyer Padmanabhan
Subramanian Baskaran
Anjaneyulu Sheri
Dillon Cleary
Ron Mastrolia
Shenghua Zhou
Sreerupa Challa
Rayomand H Gimi
Vishal Nair
Leena Praba Suppiah
Original Assignee
F Star Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72338059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2021002294(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Star Therapeutics Inc filed Critical F Star Therapeutics Inc
Publication of CL2021002294A1 publication Critical patent/CL2021002294A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C07D473/38—Sulfur atom attached in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se dan a conocer compuestos y composiciones para inhibir la expresión de un receptor de reconocimiento de patrones (por ejemplo, STING) y métodos de uso de los mismos.
CL2021002294A 2019-03-05 2021-09-02 Compuestos, composiciones y métodos para el tratamiento de enfermedad CL2021002294A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814025P 2019-03-05 2019-03-05
US201962879178P 2019-07-26 2019-07-26

Publications (1)

Publication Number Publication Date
CL2021002294A1 true CL2021002294A1 (es) 2022-04-01

Family

ID=72338059

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002294A CL2021002294A1 (es) 2019-03-05 2021-09-02 Compuestos, composiciones y métodos para el tratamiento de enfermedad

Country Status (21)

Country Link
US (1) US20220168309A1 (es)
EP (1) EP3934652A4 (es)
JP (1) JP2022525010A (es)
KR (1) KR20210135544A (es)
CN (1) CN113645977A (es)
AU (1) AU2020232761A1 (es)
BR (1) BR112021017583A2 (es)
CA (1) CA3131620A1 (es)
CL (1) CL2021002294A1 (es)
CO (1) CO2021012586A2 (es)
CR (1) CR20210508A (es)
DO (1) DOP2021000184A (es)
EC (1) ECSP21073266A (es)
IL (1) IL285782A (es)
JO (1) JOP20210244A1 (es)
MA (1) MA55214A (es)
MX (1) MX2021010701A (es)
PE (1) PE20220166A1 (es)
PH (1) PH12021552084A1 (es)
SG (1) SG11202109452SA (es)
WO (1) WO2020181050A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
PT3860998T (pt) 2018-10-05 2024-04-02 Annapurna Bio Inc Compostos e composições para o tratamento de condições associadas à atividade do recetor apj
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3876930A4 (en) 2018-11-07 2022-07-20 Dana-Farber Cancer Institute, Inc. BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
JP7770673B2 (ja) 2019-02-27 2025-11-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳障害を治療するためのアゼピノ－インドール及び他の複素環化合物
CA3149482A1 (en) 2019-08-02 2021-02-11 Mersana Therapeutics, Inc. Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
WO2021059136A1 (en) 2019-09-25 2021-04-01 Pfizer Inc. Polyheterocyclic modulators of sting (stimulator of interferon genes)
BR112022019919A2 (pt) 2020-04-02 2023-02-14 Mersana Therapeutics Inc Conjugado de anticorpo-fármaco compreendendo agonistas de sting
BR112022022409A2 (pt) 2020-05-06 2023-02-07 Ajax Therapeutics Inc 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2
CN116096378A (zh) * 2020-08-10 2023-05-09 诺华股份有限公司 视网膜变性疾病的治疗
US11767321B2 (en) 2020-10-05 2023-09-26 Enliven Inc. 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
CN114478715B (zh) * 2020-10-26 2023-12-22 南京吉芮康生物科技研究院有限公司 一种减毒沙门氏菌分泌表达s2结构域蛋白的新型冠状病毒疫苗递呈系统及其应用
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN117321055A (zh) * 2021-03-18 2023-12-29 辉瑞公司 Sting(干扰素基因刺激剂)的调节剂
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
WO2022266711A1 (en) * 2021-06-23 2022-12-29 Aculeus Therapeutics Pty Ltd Substituted amidobenzimidazole dimers as sting modulators
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
AU2022416279A1 (en) 2021-12-15 2024-07-25 Delix Therapeutics, Inc. Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
CN120659785A (zh) 2022-11-30 2025-09-16 里珍纳龙药品有限公司 Tlr7激动剂及其抗体-药物缀合物
KR20250121114A (ko) 2022-12-16 2025-08-11 아스트라제네카 아베 2,6,9-삼치환된 퓨린
CN115624616B (zh) * 2022-12-21 2023-03-14 上海市东方医院（同济大学附属东方医院） 接头蛋白pinch在诊断血管发育异常相关疾病中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920701167A (ko) * 1989-07-07 1992-08-11 에릭 에스. 딕커 약제학적 활성 화합물
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
JP4335000B2 (ja) * 2001-06-29 2009-09-30 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ｂアデノシン・レセプタ拮抗剤
WO2010017248A2 (en) * 2008-08-04 2010-02-11 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
EP3116876A4 (en) * 2014-03-13 2017-10-25 Agency For Science, Technology And Research Fused pyrimidine-based hydroxamate derivatives
GB201501462D0 (en) * 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds

Also Published As

Publication number Publication date
US20220168309A1 (en) 2022-06-02
CR20210508A (es) 2022-03-11
AU2020232761A1 (en) 2021-10-21
SG11202109452SA (en) 2021-09-29
JP2022525010A (ja) 2022-05-11
MX2021010701A (es) 2022-02-21
PE20220166A1 (es) 2022-01-28
WO2020181050A1 (en) 2020-09-10
MA55214A (fr) 2022-01-12
ECSP21073266A (es) 2021-11-30
BR112021017583A2 (pt) 2021-11-09
IL285782A (en) 2021-10-31
DOP2021000184A (es) 2021-12-15
CO2021012586A2 (es) 2021-10-20
JOP20210244A1 (ar) 2023-01-30
CA3131620A1 (en) 2020-09-10
PH12021552084A1 (en) 2022-05-30
CN113645977A (zh) 2021-11-12
EP3934652A1 (en) 2022-01-12
KR20210135544A (ko) 2021-11-15
EP3934652A4 (en) 2022-12-07

Similar Documents

Publication Publication Date Title
ECSP21073266A (es) Compuestos, composiciones y métodos para el tratamiento de enfermedad
MX2019000216A (es) Compuestos, composiciones y metodos para el tratamiento de enfermedades.
CR20190071A (es) Compuestos, composiciones y métodos para el tratamiento de enfermedades
CL2022000557A1 (es) Agonista triple de receptores de glucagón/glp-1/gip (divisional 2 solicitud 202002034)
CL2018002533A1 (es) Procedimientos para el tratamiento de la depresíón usando antagonisdas de los receptores de orexina-2.
MX2022002111A (es) Novedosos anticuerpos anti-cldn18.2.
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
CL2021000175A1 (es) Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos
BR112018006259A2 (pt) "adjunto compressível com estruturas de suporte intermediárias"
CL2019000189A1 (es) Nuevos anticuerpos anti-claudina y sus métodos de uso. (divisional solicitud 201801481)
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.
CO2021000049A2 (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos
CO2021009009A2 (es) Moduladores de la expresión de hsd17b13
MX2020003546A (es) Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
DK4025178T3 (da) Nyt system til solubilisering af fedtopløselige, organiske solfiltre
MX378806B (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas.
CR20220330A (es) Anticuerpos anti-ly6g6d y métodos de uso.
CL2019001381A1 (es) Método para el tratamiento de glomeruloesclerosis segmentaria focal.
MX2023004366A (es) Composiciones para el tratamiento de la hipertension.
CL2018002023A1 (es) Uso de moduladores de receptores de gabaa para el tratamiento de picor.
CY1125153T1 (el) Νεα ετεροκυκλικα αντiοιστρογονα
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
CO2019004164A2 (es) Compuestos de piridina bicíclicos fusionados y su uso como moduladores de receptores ampa
MX2025005302A (es) Suministro mejorado de agentes grandes
CL2020001856A1 (es) Métodos para tratar la enfermedad de farber.